1 RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth Shaikamjad Umesalma 1 , Courtney A. Kaemmer 1 , Jordan L. Kohlmeyer 2 , Blake Letney 1 , Angela M. Schab 1 , Jacqueline A. Reilly 1 , Ryan M. Sheehy 1,3 , Jussara Hagen 1 , Nitija Tiwari 1 , Fenghuang Zhan 4 , Mariah R. Leidinger 5 , Thomas M. O’Dorisio 4 , Joseph Dillon 4 , Ronald A. Merrill 1 , David K. Meyerholz 5 , Abbey L. Perl 6 , Bart J. Brown 7 , Terry A. Braun 7 , Aaron T. Scott 8 , Timothy Ginader 9 , Agshin F. Taghiyev 10 , Gideon K. Zamba 9 , James R. Howe 8 , Stefan Strack 1 , Andrew M. Bellizzi 5 , Goutham Narla 11 , Benjamin W. Darbro 10 , Frederick W. Quelle 1,4 , and Dawn E. Quelle 1,2,3,5,# The Department of Pharmacology 1 , Molecular Medicine Graduate Program 2 , Free Radical & Radiation Biology Training Program 3 and the Departments of Internal Medicine 4 , Pathology 5 , Biomedical Engineering 7 , Surgery 8 , Biostatistics 9 , and Pediatrics 10 in the Colleges of Medicine or Public Health, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa. The Department of Pharmacology 6 , Case Western Reserve University, Cleveland, Ohio. The Department of Medicine 11 , University of Michigan, Ann Arbor, Michigan. # To whom correspondence and reprint requests should be addressed: Department of Pharmacology, Carver College of Medicine, University of Iowa, 2-570 Bowen Science Bldg., Iowa City, IA 52242. Tel.: 319-353-5749; Fax: 319-335-8930; Email: dawn-quelle@uiowa.edu Conflict of interest statement: The Icahn School of Medicine on behalf of the author GN has filed patents covering composition of matter on the small molecules disclosed herein for the treatment of human cancer and other diseases and for methods of use for using these small molecule PP2A activators. RAPPTA Therapeutics LLC has licensed this intellectual property for the clinical and commercial development of this series of small molecule PP2A activators. The author GN has an ownership interest in RAPPTA Therapeutics LLC.